Back

Gene therapy for short QT syndrome type 1 (SQT1): a proof-of-concept efficacy trial in transgenic SQT1 rabbits

30 August 2025 (16:30 - 16:45)
Organised by: Logo
Congress Presentation Part of: Young Investigator Award Session in Basic and Translational Sciences Ion Channels, Electrophysiology ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Saranda Nimani

University of Bern, Bern (Switzerland)

3 More presentations in this session

Presentation thumbnail
Adverse chromatin remodelling by SETD7 drives inflammation and diastolic dysfunction in obese heart failure with preserved ejection fraction
Doctor S. Mohammed (Zurich, CH)
Abstract Slides Video
Presentation thumbnail
Human heart-tumor interaction in ischemic / failing heart is mediated by cardiac mesenchymal stromal cells
Mr T. Caller (Tel Aviv, IL)
Abstract Slides Video
Presentation thumbnail
Asxl1 clonal hematopoiesis exacerbates heart failure via the NEAT1-inflammasome axis
Doctor A. Shindo (Tokyo, JP)
Abstract Slides Video

Access the full session

Session thumbnail
Young Investigator Award Session in Basic and Translational Sciences
Video

The Event

Event poster

ESC Congress 2025

30 August 2025 16:30 CET
You may be interested in
thumbnail
Congress Presentation
In vivo KCNH2-suppression-replacement gene therapy attenuates the pathogenic phenotype in transgenic rabbits with short QT syndrome type 1
thumbnail
Congress Presentation
Gene therapy approaches to restore normal cardiac repolarisation and prevent arrhythmias in QT syndromes
thumbnail
Congress Presentation
Gene therapy in channelopathies: ready for prime time?

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources